What is the clinical evidence from this study?

Study design: Review. Population: Central nervous system disorders. Intervention: Kv7 channel modulators.

What question did this study set out to answer?

Evaluate the physiological roles, regulatory pathways, and pharmacological potential of neuronal Kv7 channels as targets for treating central nervous system diseases.

July 1, 2026Pharmacological ReviewsOpen Access

Kv7 channels as pharmacological targets for CNS diseases

View Full Paper

Ask AI

Bookmark

Key result

Kv7 channel modulators emerge as promising therapies for CNS disorders driven by neuronal excitability.

Why the study?

Neuronal Kv7 channel dysfunction contributes to various neuropsychiatric disorders, making these channels primary targets for pharmacological intervention.

Design

Review

Authors

FMFrancesco MiceliUniversity of Naples Federico II MSMaria Virginia SoldovieriUniversity of Molise VBVincenzo BarreseFederico II University Hospital

Discussion

Member takes

Implication

May support Kv7-targeted therapies in excitability disorders; leaves open clinical validation.

Key Points

Evaluate the physiological roles, regulatory pathways, and pharmacological potential of neuronal Kv7 channels as targets for treating central nervous system diseases.
Synthesized molecular and functional evidence on neuronal Kv7 channel subunits (Kv7.2–Kv7.5), developmental expression profiles, and intracellular regulatory networks.
Reviewed preclinical and clinical evidence connecting Kv7 channel dysfunction to neurological conditions, alongside current first-generation, next-generation, and repurposed modulators.
Kv7-mediated M-current establishes resting membrane potential and curbs repetitive action potential firing across diverse central neuronal populations.
Subunit mutations or aberrant regulation contribute directly to hyperexcitability phenotypes in epileptic encephalopathies, neurodegenerative conditions, and neuropathic pain.
Novel subunit-selective modulators and repurposed compounds show significant potential to overcome the clinical tolerability limitations observed with first-generation openers.

Structured PICO

Population

Patients with central nervous system disorders characterized by maladaptive changes in neuronal excitability (e.g., epileptic encephalopathies, pain syndromes, neuropsychiatric conditions, Alzheimer's disease, Parkinson's disease)

Intervention

Kv7 channel modulators (including first-generation openers like retigabine, next-generation agents, repurposed drugs, and natural products)

This review highlights the therapeutic promise of targeting Kv7 channels for various central nervous system disorders involving altered neuronal excitability.

Cite This Study

Miceli et al. (2026) conducted a review in Central nervous system disorders. Kv7 channel modulators was evaluated. Kv7 channels are versatile and highly attractive pharmacological targets for the treatment of central nervous system disorders characterized by maladaptive changes in neuronal excitability.

synapsesocial.com/papers/6aa178fd23c04e973172dfc4 https://doi.org/10.1016/j.pharmr.2026.100153

View Full Paper

Ask AI

Bookmark

Kv7 channels as pharmacological targets for CNS diseases

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Kv7 channels as pharmacological targets for CNS diseases

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider